|
| 36602514 | Improved Survival After Adjuvant Therapy in Locally Advanced Rectal Cancer Patients With Pathologic Complete Response. | Dis Colon Rectum | 2023 |
| 37772994 | Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. | Cancer Res Commun | 2023 |
| 37391327 | Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. | Surgery | 2023 |
| 37379764 | Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial. | ESMO Open | 2023 |
| 37309603 | Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. | Clin Cancer Res | 2023 |
| 37308125 | Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2023 |
| 34716197 | Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. | Clin Cancer Res | 2022 |
| 36970055 | A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. | Cancer Res Commun | 2022 |
| 36969746 | A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01). | Cancer Res Commun | 2022 |
| 36419897 | Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. | Front Oncol | 2022 |
| 36309653 | ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. | BMC Cancer | 2022 |
| 36240850 | Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 36240469 | Tissue Displacement Versus Two Primary Colorectal Carcinomas? A Case Report on the Utility of Comparative Sequencing. | JCO Precis Oncol | 2022 |
| 35192363 | Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. | J Med Chem | 2022 |
| 35288468 | Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. | J Immunother Cancer | 2022 |
| 34862244 | Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma. | Clin Cancer Res | 2022 |
| 32997608 | Benchmarks for Academic Oncology Faculty. | JCO Oncol Pract | 2021 |
| 33854497 | Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. | Front Immunol | 2021 |
| 33742123 | Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer. | Oncogene | 2021 |
| 33741442 | Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. | Ann Oncol | 2021 |
| 33850005 | Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology? | Mol Cancer Ther | 2021 |
| 33869031 | WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. | Front Oncol | 2021 |
| 33777751 | Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers. | Front Oncol | 2021 |
| 33724754 | Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 33526513 | Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. | Cancer Res | 2021 |
| 34793719 | Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. | Lancet Oncol | 2021 |
| 34790407 | Neoadjuvant treatment of localized pancreatic adenocarcinoma. | J Gastrointest Oncol | 2021 |
| 34541862 | Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases. | J Clin Oncol | 2021 |
| 34155509 | Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. | Br J Surg | 2021 |
| 33277184 | Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. | HPB (Oxford) | 2021 |
| 33097963 | Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. | Cancer Immunol Immunother | 2021 |
| 31338636 | A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. | Invest New Drugs | 2020 |
| 32634771 | NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. | J Natl Compr Canc Netw | 2020 |
| 32816368 | Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. | Mol Carcinog | 2020 |
| 32694153 | Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. | Clin Cancer Res | 2020 |
| 32219196 | Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. | J Pancreat Cancer | 2020 |
| 32414750 | Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. | Clin Cancer Res | 2020 |
| 32499299 | First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. | Mol Cancer Ther | 2020 |
| 32204315 | Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. | Cancers (Basel) | 2020 |
| 31513709 | Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment. | J Clin Endocrinol Metab | 2020 |
| 30944125 | Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. | Clin Cancer Res | 2019 |
| 31675229 | Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. | J Med Chem | 2019 |
| 31398063 | Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. | Expert Rev Anticancer Ther | 2019 |
| 30736857 | Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. | J Immunother Cancer | 2019 |
| 31117039 | NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer. | J Natl Compr Canc Netw | 2019 |
| 28887726 | Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. | Ann Surg Oncol | 2018 |
| 30026382 | Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. | Mol Cancer Ther | 2018 |
| 30048249 | Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. | Anticancer Drugs | 2018 |
| 30042150 | Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. | Cancer Res | 2018 |
| 30139840 | A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. | Oncologist | 2018 |